UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.114

Sortiert nach

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis

Arthritis care & research (2010), 2016-06, Vol.68 (6), p.838-844

2016

Volltextzugriff (PDF)

Effect of Certolizumab Pegol Over Ninety‐Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

Arthritis & rheumatology (Hoboken, N.J.), 2015-03, Vol.67 (3), p.668-677

2015

Volltextzugriff (PDF)

Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

Arthritis care & research (2010), 2017-07, Vol.69 (7), p.1030-1039

2017

Volltextzugriff (PDF)

Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial

Clinical rheumatology, 2018-12, Vol.37 (12), p.3285-3296

2018

Volltextzugriff (PDF)

Search for KPNA7 cargo proteins in human cells reveals MVP and ZNF414 as novel regulators of cancer cell growth

Biochimica et biophysica acta. Molecular basis of disease, 2017-01, Vol.1863 (1), p.211-219

2017

Volltextzugriff (PDF)

THU0380 A Single Determination of C-Reactive Protein Does Not Suffice To Declare A Patient with A Diagnosis of Axial SPA “CRP-Negative”

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.325-325

2016

Volltextzugriff (PDF)

Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial

Clinical rheumatology, 2018-12, Vol.37 (12), p.3297-3297

2018

Volltextzugriff (PDF)

SAT0403 Further Analysis of Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) Using Data from A Placebo-Controlled TRIAL of Certolizumab Pegol in Psoriatic Arthritis

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.740-740

2014

Volltextzugriff (PDF)

SAT0405 Disease Activity and Clinical Response Early in the Course of Treatment PREDICT Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.741-741

2014

Volltextzugriff (PDF)

SAT0338 Disease Activity and Clinical Response Early in the Course of Treatment PREDICT Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.714-715

2014

Volltextzugriff (PDF)

SAT0362 Certolizumab Pegol Rapidly Reduces Peripheral Enthesitis and the Incidence of Tender and Swollen Joints in Patients with Active Axial Spondyloarthritis, Including Both Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.724-725

2014

Volltextzugriff (PDF)

THU0201 Factors Associated with Structural Damage in the Spine, as Measured by X-ray, in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol Over 96 Weeks

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.268-268

2015

Volltextzugriff (PDF)

OP0171 Achievement of Remission of Inflammation in the Spine and Sacroiliac Joints Measured by Magnetic Resonance Imaging (MRI) in Patients with Axial Spondyloarthritis, and Associations Between MRI and Clinical Remission, Over 96 Weeks of Treatment with Certolizumab Pegol

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.134-135

2015

Volltextzugriff (PDF)

SAT0545 Comparing Health-Related Quality of Life across Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis: Analyses from Certolizumab Pegol Clinical Trial Baseline Data

Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A766-A767

2013

Volltextzugriff (PDF)

SAT0355 Observed Incidence Rates of Uveitis following Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.721-722

2014

Volltextzugriff (PDF)

SAT0351 Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Outcomes of the Rapid-Axspa Trial

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.719-720

2014

Volltextzugriff (PDF)

Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa Study

Value in health, 2014-11, Vol.17 (7), p.A385-A386

2014

Volltextzugriff (PDF)

Comparing Health-Related Quality of Life Across Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis: Analyses from Certolizumab Pegol Clinical Trial Baseline Data

Value in health, 2013-11, Vol.16 (7), p.A570-A570

2013

Volltextzugriff (PDF)

The Epidemiologic Study of Birth Defects and Pesticides

Epidemiology (Cambridge, Mass.), 2001-03, Vol.12 (2), p.145-146

Nurminen, Tuula

2001

Volltextzugriff (PDF)

PBI6 Stringent Thresholds of Disease Control Are Associated with Reduced Burden on Paid and Household Work Productivity in Patients with Psoriatic Arthritis during LONG-TERM Treatment with Certolizumab Pegol

Value in health, 2020-12, Vol.23, p.S411-S411

2020

Volltextzugriff (PDF)

Multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling

The American journal of psychiatry, 2006-02, Vol.163 (2), p.303-312

2006

Volltextzugriff (PDF)

Indoor green wall affects health-associated commensal skin microbiota and enhances immune regulation: a randomized trial among urban office workers

Scientific reports, 2022-04, Vol.12 (1), p.6518-9, Article 6518

2022

Volltextzugriff (PDF)

Shift work and reproductive health

Scandinavian journal of work, environment & health, 1998-01, Vol.24, p.28-34

Nurminen, Tuula

1998

Volltextzugriff (PDF)

Certolizumab Pegol is Associated with Long-Term Improvements in Patient-Reported Outcomes in Axial Spondyloarthritis Patients, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 4-Year Outcomes from the Rapid-Axspa Study

Value in health, 2016-11, Vol.19 (7), p.A595-A595

2016

Volltextzugriff (PDF)

PSY114 - Certolizumab Pegol is Associated with Long-Term Improvements in Patient-Reported Outcomes in Axial Spondyloarthritis Patients, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 4-Year Outcomes from the Rapid-Axspa Study

Value in health, 2016-11, Vol.19 (7), p.A595-A595

2016

Volltextzugriff (PDF)

1 – 25 von 1.114

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(856)
Mit Volltextzugriff
(999)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.094)
Japanisch
(92)
Finnisch
(16)
Deutsch
(4)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(692)
Life Sciences & Biomedicine
(480)
Humans
(311)
Male
(191)
Technology
(176)
Female
(158)
Biological And Medical Sciences
(157)
Adult
(111)
Middle Aged
(110)
Computer Science
(105)
Medical Sciences
(96)
Animals
(84)
Finland
(82)
Engineering
(81)
Physical Sciences
(77)
Aged
(76)
Fundamental And Applied Biological Sciences. Psychology
(70)
Public, Environmental & Occupational Health
(69)
Environmental Sciences & Ecology
(59)
Engineering, Electrical & Electronic
(54)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Scandinavian Journal Of Work, Environment & Health
(45)
Plos One
(19)
European Urology
(14)
Infection And Immunity
(13)
Annals Of The Rheumatic Diseases
(12)
Hydrobiologia
(10)
Acta Neurochirurgica
(9)
Epidemiology
(9)
Critical Care
(8)
Duodecim
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(16)
... seit 30 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis

Effect of Certolizumab Pegol Over Ninety‐Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial

Search for KPNA7 cargo proteins in human cells reveals MVP and ZNF414 as novel regulators of cancer cell growth

THU0380 A Single Determination of C-Reactive Protein Does Not Suffice To Declare A Patient with A Diagnosis of Axial SPA “CRP-Negative”

Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial

SAT0403 Further Analysis of Psoriatic Arthritis Disease Activity Score (PASDAS) and Composite Psoriatic Disease Activity Index (CPDAI) Using Data from A Placebo-Controlled TRIAL of Certolizumab Pegol in Psoriatic Arthritis

SAT0405 Disease Activity and Clinical Response Early in the Course of Treatment PREDICT Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

SAT0338 Disease Activity and Clinical Response Early in the Course of Treatment PREDICT Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol

SAT0362 Certolizumab Pegol Rapidly Reduces Peripheral Enthesitis and the Incidence of Tender and Swollen Joints in Patients with Active Axial Spondyloarthritis, Including Both Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

THU0201 Factors Associated with Structural Damage in the Spine, as Measured by X-ray, in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol Over 96 Weeks

OP0171 Achievement of Remission of Inflammation in the Spine and Sacroiliac Joints Measured by Magnetic Resonance Imaging (MRI) in Patients with Axial Spondyloarthritis, and Associations Between MRI and Clinical Remission, Over 96 Weeks of Treatment with Certolizumab Pegol

SAT0545 Comparing Health-Related Quality of Life across Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis: Analyses from Certolizumab Pegol Clinical Trial Baseline Data

SAT0355 Observed Incidence Rates of Uveitis following Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis

SAT0351 Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Outcomes of the Rapid-Axspa Trial

Long-Term Maintenance of Improvements in Patient-Reported Outcomes With Certolizumab Pegol in Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Results of the Rapid-Axspa Study

Comparing Health-Related Quality of Life Across Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis: Analyses from Certolizumab Pegol Clinical Trial Baseline Data

The Epidemiologic Study of Birth Defects and Pesticides

PBI6 Stringent Thresholds of Disease Control Are Associated with Reduced Burden on Paid and Household Work Productivity in Patients with Psoriatic Arthritis during LONG-TERM Treatment with Certolizumab Pegol

Multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling

Indoor green wall affects health-associated commensal skin microbiota and enhances immune regulation: a randomized trial among urban office workers

Shift work and reproductive health

Certolizumab Pegol is Associated with Long-Term Improvements in Patient-Reported Outcomes in Axial Spondyloarthritis Patients, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 4-Year Outcomes from the Rapid-Axspa Study

PSY114 - Certolizumab Pegol is Associated with Long-Term Improvements in Patient-Reported Outcomes in Axial Spondyloarthritis Patients, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 4-Year Outcomes from the Rapid-Axspa Study

Suchergebnisse filtern